eltoprazine
Sign in to saveEltoprazine (; developmental code name DU-28,853) is a non-selective serotonin receptor modulator of the phenylpiperazine family which was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, drug-induced dyskinesia, and psychotic disorders but was never marketed. It has been described as a "serenic" or antiaggressive agent. The drug is taken orally.
Research
96 papers- Pharmacokinetic evaluation of eltoprazine.Expert opinion on drug metabolism & toxicology · 2011
- Eltoprazine modulated gamma oscillations on ameliorating L-dopa-induced dyskinesia in rats.CNS neuroscience & therapeutics · 2023
- Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.Brain : a journal of neurology · 2015
- Behavioural pharmacology of the serenic, eltoprazine.Drug metabolism and drug interactions · 1990
- Neurochemical profile of eltoprazine.Drug metabolism and drug interactions · 1990
via PubMed
~2 min read
Encyclopedic overview
3 sectionsContents
- See also
- References
- External links
Eltoprazine (; developmental code name DU-28,853) is a non-selective serotonin receptor modulator of the phenylpiperazine family which was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, drug-induced dyskinesia, and psychotic disorders but was never marketed. It has been described as a "serenic" or antiaggressive agent. The drug is taken orally.
It acts as an agonist of the serotonin 5-HT1A and 5-HT1B receptors and as an antagonist of the serotonin 5-HT2C receptor (Ki = 40nM, 52nM, and 81nM, respectively). The drug also shows weaker affinity for certain other serotonin receptors and targets. The pharmacokinetics of eltoprazine have been studied. Eltoprazine is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan.
Excerpted from Wikipedia’s “eltoprazine” article, available under the CC BY-SA 4.0 licence.